In an experimental cancer model, combining three treatments produced a far greater antitumor response than the corresponding two-treatment approaches.

Lévesque and colleagues (2019) investigated a combination of immunogenic chemotherapy, PD-1/PD-L1 checkpoint blockade and a metabolic intervention such as fasting or caloric-restriction mimetics, including hydroxycitrate and spermidine.
The triple approach produced durable tumor control, including long-term survivors, in experimental mouse models. The individual treatments and partial combinations were much less effective.
The point is not that fasting alone cures cancer. It is that chemotherapy-induced tumor-cell death, immune checkpoint release and metabolic intervention can reinforce one another. That makes intelligently designed combinations particularly interesting for future research.
Source: Lévesque et al. (2019), OncoImmunology, doi:10.1080/2162402X.2019.1657375.
